Tag - BTX

Markets

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

May 26, 2022

Markets

Maxim starts Brooklyn ImmunoTherapeutics at buy; PT $20

Maxim Group launched coverage of Brooklyn ImmunoTherapeutics (NYSE American:BTX) with a “buy” rating and $20 price target. The stock finished at $9.01 on Oct. 5. Brooklyn is developing two therapeutic platforms in...

October 6, 2021

Feature

BioTime leading advances in regenerative medicine

By Len Zehr BioTime (NYSE:MKT, TASE:BTX) has multiple data milestones scheduled this year in its two lead regenerative medicine programs: OpRegen in dry AMD and Renevia in facial aesthetics. “We believe we are one of...

January 24, 2017

Tag - BTX

Maxim reduces PTs in challenging biotech market

Maxim starts Brooklyn ImmunoTherapeutics at buy; PT $20

BioTime leading advances in regenerative medicine

General

More